Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
Katelyn T. Byrne,Courtney B. Betts,Rosemarie Mick,Shamilene Sivagnanam,David L. Bajor,Daniel A. Laheru,E. Gabriela Chiorean,Mark H. O'Hara,Shannon M. Liudahl,Craig Newcomb,Cecile Alanio,Ana P. Ferreira,Byung S. Park,Takuya Ohtani,Austin P. Huffman,Sara A. Vayrynen,Andressa Dias Costa,Judith C. Kaiser,Andreanne M. Lacroix,Colleen Redlinger,Martin Stern,Jonathan A. Nowak,E. John Wherry,Martin A. Cheever,Brian M. Wolpin,Emma E. Furth,Elizabeth M. Jaffee,Lisa M. Coussens,Robert H. Vonderheide Clinical Cancer Research（2021）
Key words
Neoadjuvant Therapy,Tumor Microenvironment
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper